# OnCo record paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026" ;
  schema:name "Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial"@en ;
  schema:description "Phase 2 or 3 results paper on Trastuzumab deruxtecan in HR-positive / HER2-negative breast cancer, in Annals of Oncology (2026), one of the most cited Europe PMC records with Trastuzumab deruxtecan in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2025.10.019>, <https://pubmed.ncbi.nlm.nih.gov/41130363/>, <https://europepmc.org/article/MED/41130363> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2025.10.019> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Harbeck N, Modi S, Pusztai L, et al." ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .